Acer Therapeutics Inc. – NASDAQ:ACER

Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9

Acer Therapeutics stock price monthly change

-20.20%
month

Acer Therapeutics stock price quarterly change

-9.22%
quarter

Acer Therapeutics stock price yearly change

-44.07%
year

Acer Therapeutics key metrics

Market Cap
N/A
Enterprise value
15.36M
P/E
-0.56
EV/Sales
N/A
EV/EBITDA
-0.40
Price/Sales
N/A
Price/Book
-0.91
PEG ratio
0.01
EPS
-2.85
Revenue
N/A
EBITDA
-9.91M
Income
-60.92M
Revenue Q/Q
N/A
Revenue Y/Y
3.27%
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Acer Therapeutics stock price history

Acer Therapeutics stock forecast

Acer Therapeutics financial statements

Acer Therapeutics Inc. (NASDAQ:ACER): Profit margin
Dec 2022 0 -11.23M
Mar 2023 0 -26.85M
Jun 2023 0 -8.09M
Sep 2023 371.79K -14.73M -3962.25%
Acer Therapeutics Inc. (NASDAQ:ACER): Analyst Estimates
2025 109.94M 27.89M 25.37%
  • Analysts Price target

  • Financials & Ratios estimates

Acer Therapeutics Inc. (NASDAQ:ACER): Debt to assets
Dec 2022 11624226 28.38M 244.19%
Mar 2023 15672096 41.78M 266.62%
Jun 2023 14648276 47.89M 326.96%
Sep 2023 14002065 61.74M 440.99%
Acer Therapeutics Inc. (NASDAQ:ACER): Cash Flow
Dec 2022 -8.29M -135.33K 4.38M
Mar 2023 -9.01M -3.06K 13.07M
Jun 2023 -5.50M 0 677.62K
Sep 2023 -15.99M 0 6.17M

Acer Therapeutics alternative data

Acer Therapeutics Inc. (NASDAQ:ACER): Employee count
Aug 2023 33
Sep 2023 30
Oct 2023 30
Nov 2023 30
Dec 2023 30
Jan 2024 30
Feb 2024 30
Mar 2024 30
Apr 2024 30
May 2024 30
Jun 2024 30
Jul 2024 30

Acer Therapeutics other data

9.95% -0.32%
of ACER is owned by hedge funds
1.41M -49.99K
shares is hold by hedge funds

Acer Therapeutics Inc. (NASDAQ:ACER): Insider trades (number of shares)
Period Buy Sel
Dec 2021 10000 0
Nov 2022 1229508 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
ASELAGE STEVE director
Common Stock 409,836 $1.22 $500,000
Purchase
SCHELLING CHRIS director, 10 percent owner, off..
Common Stock 819,672 $1.22 $1,000,000
Purchase
ASELAGE STEVE director
Common Stock 7,984 $2.04 $16,287
Purchase
ASELAGE STEVE director
Common Stock 2,016 $2.15 $4,334
Purchase
JOSEPH DONALD officer: Chief Le.. Common Stock 14,285 $3.5 $49,998
Purchase
SCHELLING CHRIS director, 10 percent owner, off..
Common Stock 142,857 $3.5 $500,000
Purchase
ASELAGE STEVE director
Common Stock 45,000 $3.5 $157,500
Purchase
DUNN JOHN MICHAEL director
Common Stock 21,428 $3.5 $74,998
Purchase
ASELAGE STEVE director
Common Stock 5,000 $3.72 $18,580
Purchase
TVM LIFE SCIENCE VENTURES VII L.P. director, 10 percent owner
Common Stock 275,000 $18 $4,950,000
Patent
Application
Filling date: 3 Dec 2021 Issue date: 9 Jun 2022
Grant
Filling date: 9 Mar 2021 Issue date: 21 Dec 2021
Grant
Filling date: 9 Mar 2021 Issue date: 26 Oct 2021
Application
Filling date: 9 Mar 2021 Issue date: 22 Jul 2021
Application
Filling date: 9 Mar 2021 Issue date: 24 Jun 2021
Application
Filling date: 17 Jan 2020 Issue date: 20 Aug 2020
Tuesday, 22 October 2024
rt.com
Thursday, 2 November 2023
globenewswire.com
Friday, 20 October 2023
CNBC
Friday, 1 September 2023
Zacks Investment Research
Thursday, 31 August 2023
InvestorPlace
Monday, 20 March 2023
Zacks Investment Research
Sunday, 5 March 2023
InvestorPlace
Wednesday, 18 January 2023
Zacks Investment Research
Monday, 16 January 2023
Zacks Investment Research
Thursday, 29 December 2022
Zacks Investment Research
Wednesday, 28 December 2022
Zacks Investment Research
Zacks Investment Research
Tuesday, 13 December 2022
Zacks Investment Research
Tuesday, 23 August 2022
GlobeNewsWire
Friday, 15 July 2022
Zacks Investment Research
Friday, 8 July 2022
Zacks Investment Research
Tuesday, 28 June 2022
Zacks Investment Research
Thursday, 23 June 2022
Zacks Investment Research
Tuesday, 21 June 2022
Benzinga
Zacks Investment Research
Wednesday, 15 June 2022
Zacks Investment Research
Thursday, 9 June 2022
Zacks Investment Research
Monday, 6 June 2022
Zacks Investment Research
Friday, 27 May 2022
Zacks Investment Research
Monday, 16 May 2022
Zacks Investment Research
Monday, 9 May 2022
PennyStocks
Thursday, 5 May 2022
GlobeNewsWire
Tuesday, 8 February 2022
Zacks Investment Research
Tuesday, 1 February 2022
GlobeNewsWire
Thursday, 13 January 2022
Zacks Investment Research
  • When is Acer Therapeutics's next earnings date?

    Unfortunately, Acer Therapeutics's (ACER) next earnings date is currently unknown.

  • Does Acer Therapeutics pay dividends?

    No, Acer Therapeutics does not pay dividends.

  • What is Acer Therapeutics's stock symbol?

    Acer Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "ACER".

  • What is Acer Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Acer Therapeutics?

    Shares of Acer Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Acer Therapeutics's key executives?

    Acer Therapeutics's management team includes the following people:

    • Mr. Christopher Schelling Founder, Pres, Chief Executive Officer & Director(age: 49, pay: $675,800)
    • Mr. Harry S. Palmin Chief Operating Officer & Chief Financial Officer(age: 55, pay: $535,360)
    • Mr. Donald R. Joseph J.D. Chief Legal Officer & Sec.(age: 71, pay: $490,280)
  • Is Acer Therapeutics founder-led company?

    Yes, Acer Therapeutics is a company led by its founder Mr. Christopher Schelling.

  • How many employees does Acer Therapeutics have?

    As Jul 2024, Acer Therapeutics employs 30 workers.

  • When Acer Therapeutics went public?

    Acer Therapeutics Inc. is publicly traded company for more then 21 years since IPO on 14 Apr 2004.

  • What is Acer Therapeutics's official website?

    The official website for Acer Therapeutics is acertx.com.

  • Where are Acer Therapeutics's headquarters?

    Acer Therapeutics is headquartered at One Gateway Center, Newton, MA.

  • How can i contact Acer Therapeutics?

    Acer Therapeutics's mailing address is One Gateway Center, Newton, MA and company can be reached via phone at +84 49026100.

Acer Therapeutics company profile:

Acer Therapeutics Inc.

acertx.com
Exchange:

NASDAQ

Full time employees:

30

Industry:

Biotechnology

Sector:

Healthcare

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

One Gateway Center
Newton, MA 02458

CIK: 0001069308
ISIN: US00444P1084
CUSIP: 00444P108